Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
November 17, 2003
- Daiichi: Cravit, Artist Contribute to Good Sales
November 17, 2003
- Soiken to Develop Biomarkers for Fatigue
November 17, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 17, 2003
- Drugstore Chains Using Weather Derivatives to Avoid Risk
November 17, 2003
- Basic Policy for Next NHI Pricing Reform Proposed to Chuikyo Subcommittee
November 17, 2003
- Banyu Presents 1st Report on Its Large Japanese Study on Nu-Lotan
November 17, 2003
- NEW PRODUCTS
November 17, 2003
- MRA Effective against Adult RA, JIA: Chugai
November 17, 2003
- BULLETIN
November 17, 2003
- SEMIANNUAL BUSINESS RESULTS
November 17, 2003
- BUSINESS NEWS IN BRIEF
November 17, 2003
- Press Seminar
November 17, 2003
- Industry Polarization Became Marked in the Last Decade
November 17, 2003
- MEDICAL DEVICE NEWS IN BRIEF
November 17, 2003
- Taiyo Pharmaceutical: Sales Up 46.0%, Ordinary Profits Up 86.0%
November 17, 2003
- Chuikyo Subcommittee to Review Pricing of Insurance-covered Medical Materials
November 17, 2003
- JT: Pharma Division Sales Down 4.3%
November 17, 2003
- JCQHC Warns Against High-concentration K Preparations, 10% Xylocaine
November 17, 2003
- Kyorin: Sales Down 3.3% due to Decline in Sales of Gatiflo
November 17, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…